Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.

ABSTRACT:

Background

For patients on oral anticoagulants (OAC) undergoing percutaneous coronary intervention (PCI), European guidelines have recently changed their recommendations to dual antithrombotic therapy (DAT; P2Y₁₂ inhibitor and OAC) without aspirin.

Aims

The prospective WOEST 2 registry was designed to obtain contemporary real-world data on antithrombotic regimens and related outcomes after PCI in patients with an indication for OAC.

Methods

In this analysis, we compare DAT (P2Y₁₂ inhibitor and OAC) to triple antithrombotic therapy (TAT; aspirin, P2Y₁₂ inhibitor, and OAC) on thrombotic and bleeding outcomes after one year. Clinically relevant bleeding was defined as Bleeding Academic Research Consortium classification (BARC) grade 2, 3,

SUBMITTER: Bor WL 

PROVIDER: S-EPMC9980408 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature